annual report, page-10

OK what do we have ....

1) first commercial polyprenols manufacturing facility in the world
2) Currently producing 3,000 courses p/mth estimated at US$1125 = 12m Annual profit / 220m share capital x 15 PE = 82c p/share today
3) likely registartion of BioA as a pharmaceutical to treat gastro (affecting 50% of the WORLDS population)
4) Dump in equities .. should see support in SP as market rebounds
5) Launch of Bio I - a antioxidant drink allready trialled by some sports personalities (that's the way)
6) AGM last week in Nov, requires 28 days notice of items requirinfg shareholder resolution (news is coming)
7) Directors believe that the initial marketing of Ropren in Russia will provide strong SALES revenue to the group for the 08/09 fin yr

Thanks for the support ...